Pharma association denies pandemic lobbying: "Interest protection was on standby"

Though a new report points to increased pharma lobbying during the pandemic, a Danish trade association says public and private actors came together to solve the crisis in Denmark.
Henrik Vestergaard, deputy director at Lif | Photo: Lif / Pr
Henrik Vestergaard, deputy director at Lif | Photo: Lif / Pr
by ulrich quistgaard, translated by daniel pedersen

When the Covid-19 pandemic made its way around the world, European policymakers, facing an acute need for vaccines, buckled under lobbying efforts, leading to higher prices and less transparency, a new report concludes.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading